Seres Therapeutics
MCRB
99 hedge funds and large institutions have $66.8M invested in Seres Therapeutics in 2024 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 28 increasing their positions, 28 reducing their positions, and 24 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 28
0.62% less ownership
Funds ownership: 3.46% → 2.84% (-0.62%)
3% less funds holding
Funds holding: 102 → 99 (-3)
13% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 24
14% less call options, than puts
Call options by funds: $408K | Put options by funds: $477K
47% less capital invested
Capital invested by funds: $126M → $66.8M (-$59.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.52M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.19M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$815K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$787K |
| 5 |
Goldman Sachs
New York
|
+$677K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.01M |
| 2 |
Millennium Management
New York
|
-$1.29M |
| 3 |
Renaissance Technologies
New York
|
-$1.14M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$955K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$897K |
MCRB Hedge Fund Activity: Q1 2024 in Review
99 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q1 2024, worth a combined $66.8M — down 47% from $126M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of MCRB and 21 opened new positions — a net loss of 3 holders — while 28 trimmed existing stakes and 28 added.
The largest buyer was Fidelity Investments, adding an estimated $3.52M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $3.01M sold.
- 99 institutional investors held Seres Therapeutics (MCRB) as of Q1 2024, down from 102 in Q4 2023.
- Funds reported $66.8M of Seres Therapeutics stock for Q1 2024, down 47% quarter-over-quarter.
- 21 funds opened new Seres Therapeutics positions in Q1 2024 and 24 closed out, a net change of -3 holders.
- The largest Seres Therapeutics buyer in Q1 2024 was Fidelity Investments, an estimated $3.52M added.
- The largest Seres Therapeutics seller in Q1 2024 was Point72 Asset Management, an estimated $3.01M sold.
Based on aggregated 13F filings for Q1 2024.